Mazdutide

Inquiry

Cat Number

API2259884030

CAS Number

2259884-03-0

If you have any other questions, please contact our experts.

Product Detail Description Scientific Support Customer Q&A

CAS Number

2259884-03-0

Storage

2-8℃

Molecular Formula

C210H322N46O67

Molecular Weight

4563.14

Smiles

C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC4=CC=CC=C4)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C(C)(C)NC(=O)[C@H](CC8=CNC=N8)N)O

Appearance

White powder

General Description

Mazdutide is a long-acting synthetic peptide that functions as a dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Developed as a next-generation treatment for metabolic disorders, it is a specialized derivative of oxyntomodulin. By targeting both receptors, it offers a more comprehensive approach to managing metabolic health compared to traditional mono-agonists, making it a high-value molecule in pharmaceutical research and clinical development.

Mechanism of Action

Mazdutide exerts its effects through a synergistic dual-pathway mechanism. Activation of the GLP-1 receptor stimulates glucose-dependent insulin secretion, slows gastric emptying, and suppresses appetite via central nervous system signaling. Concurrently, its activation of the glucagon receptor increases energy expenditure by promoting thermogenesis and modulating lipid metabolism in the liver. This dual agonism not only facilitates superior glycemic control but also enhances weight loss by combining appetite suppression with increased metabolic rate.

Application

Mazdutide is primarily utilized in the clinical development of therapeutic interventions for chronic weight management and type 2 diabetes mellitus. Its unique ability to regulate both glucose levels and energy balance makes it a candidate for treating non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Mazdutide is a dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), on diabetes-associated cognitive dysfunction (DACD). Using a db/db mouse model, the research compared different doses of Mazdutide against Dulaglutide (a GLP-1R mono-agonist) and controls, employing behavioral tests, pathological analyses, and multi-omics profiling.
The results showed that Mazdutide dose-dependently reduced body weight, blood glucose, and food intake, and alleviated hepatic steatosis. Behaviorally, high-dose Mazdutide significantly outperformed Dulaglutide in improving cognitive performance in tests like the Morris water maze and novel object recognition. Pathologically, it mitigated neuronal damage and death in the hippocampus, increased Nissl bodies and NeuN/MAP2-positive signals, promoted myelin repair and dendritic spine density, and enhanced the expression of synaptic plasticity-related genes.
Multi-omics analysis revealed that Mazdutide's key mechanism involves downregulating the vesicular glutamate transporter VGlut2 (Slc17a6), thereby reducing glutamate excitotoxicity. It also modulated the NMDA/GABA receptor balance to restore excitatory/inhibitory (E/I) homeostasis. Furthermore, it activated cAMP/PKA and PI3K-Akt signaling pathways, regulating CPEB family members, and impacting amino acid and lipid metabolism.

Fig. 1 Schematic illustration of the potential mechanisms of Mazdutide. (Dong W.; et al. 2025)

References

Dong W, et al. Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis. EBioMedicine, 2025, 117.

What makes Mazdutide different from Semaglutide?

Unlike semaglutide, which is a GLP-1 mono-agonist, Mazdutide is a dual agonist that targets both the GLP-1 and glucagon receptors.

How does the glucagon receptor agonism contribute to its effect?

It helps increase energy expenditure and promotes the breakdown of fats, which complements the appetite suppression of the GLP-1 component.

What is the primary target of Mazdutide in clinical research?

It is primarily studied for its efficacy in significant weight reduction and the improvement of glycemic control in metabolic disorders.

Are technical documents like COA and SDS available?

Yes, every batch is supplied with a batch-specific Certificate of Analysis.